论文部分内容阅读
目的分析高分级脑胶质瘤患者术后同步放化疗的疗效。方法对该院收治的65例高分级脑胶质瘤术后患者(其中Ⅲ级脑胶质瘤37例,Ⅳ级28例)均给予术后放疗肿瘤剂量(DT)50～60Gy,同时于DT20Gy后行同步替尼泊甙(VM-26)联合司莫司汀(Me-CCNU)化疗,于放疗开始后4～6个月内完成4～6周期的化疗。结果高分级脑胶质瘤患者总的中位生存期为24个月,1、3、5年生存率分别为70.77%、31.22%、12.65%。Ⅳ级胶质瘤生存率明显低于Ⅲ级胶质瘤(P(0.01),Ⅳ级与Ⅲ级脑胶质瘤的中位生存期分别为14个月及36个月,1、3、5年生存率分别为60.71%、8.04%、0及78.38%、48.03%、21.76%。结论高分级脑胶质瘤患者术后行放疗同步VM-26联合Me-CCNU方案化疗可取得较好的预后,尤其是Ⅲ级脑胶质瘤患者。
Objective To analyze the curative effect of concurrent chemoradiotherapy in patients with high grade gliomas. Methods Totally 65 patients with high grade glioma admitted to our hospital (37 in grade Ⅲ glioma and 28 in grade Ⅳ) were treated with radiotherapy (50-60 Gy) Chemotherapy after 4 to 6 cycles of VM-26 and Me-CCNU was performed in 4 to 6 months after the start of radiotherapy. Results The overall median survival of patients with high grade gliomas was 24 months. The 1, 3, 5 year survival rates were 70.77%, 31.22% and 12.65%, respectively. The survival rate of grade IV glioma was significantly lower than that of grade III glioma (P <0.01). The median survival time of grade IV and grade III glioma was 14 months and 36 months respectively, The annual survival rate was 60.71%, 8.04%, 0 and 78.38%, 48.03% and 21.76%, respectively.Conclusion The high grade glioma patients undergoing postoperative radiotherapy combined with VM-26 and Me-CCNU regimen can achieve better prognosis , Especially grade III glioma patients.